Quality of Life in Myeloproliferative Neoplasms: Symptoms and Management Implications
- PMID: 33641875
- DOI: 10.1016/j.hoc.2020.12.006
Quality of Life in Myeloproliferative Neoplasms: Symptoms and Management Implications
Abstract
Myeloproliferative neoplasms include essential thrombocythemia, polycythemia vera, and myelofibrosis. They are characterized by abnormal myeloid proliferation. Patients suffer from debilitating constitutional symptoms and splenomegaly. There have been advances in understanding the impact on quality of life in myeloproliferative neoplasms. Owing to the chronicity of these diseases, symptoms are considered in response criteria for clinical trials. This review wills cover how quality of life is measured in patients with myeloproliferative neoplasm. We review the impact of treatment options, including JAK inhibitors, allogeneic stem cell transplantation, and medications in development. We discuss nonpharmacologic methods of improving symptoms and quality of life.
Keywords: Inflammation; Integrative medicine; Myeloproliferative neoplasm; Quality of life.
Copyright © 2020 Elsevier Inc. All rights reserved.
Conflict of interest statement
Disclosure Authors have nothing to disclose.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources